Submission for OMB Review; 30-Day Comment Request Rapid Throughput Standardized Evaluation of Transmissible Risk for Substance Use Disorder in Youth, 16802-16803 [2014-06728]
Download as PDF
16802
Federal Register / Vol. 79, No. 58 / Wednesday, March 26, 2014 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request Rapid Throughput
Standardized Evaluation of
Transmissible Risk for Substance Use
Disorder in Youth
Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below. This proposed information
collection was previously published in
the Federal Register on December 3,
2013, page 72682–72683 and allowed
60-days for public comment. One public
comment was received. The purpose of
this notice is to allow an additional 30
days for public comment. The National
Institute Drug Abuse (NIDA), National
Institutes of Health, may not conduct or
sponsor, and the respondent is not
required to respond to, an information
collection that has been extended,
revised, or implemented on or after
October 1, 1995, unless it displays a
currently valid OMB control number.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the: Office
of Management and Budget, Office of
Regulatory Affairs,
OIRA_submission@omb.eop.gov or by
fax to 202–395–6974, Attention: NIH
Desk Officer.
DATES: Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30-days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instructions, contact Dr.
Augie Diana, Health Scientist
Administrator, Prevention Research
Branch, Division of Epidemiology,
Services, and Prevention Research,
NIDA, NIH, 6001 Executive Boulevard,
SUMMARY:
Room 5163, Bethesda, MD 20892, or call
non-toll-free number (301) 443–1942 or
Email your request, including your
address to: dianaa@nida.nih.gov.
Formal request for additional plans and
instruments must be requested in
writing.
Proposed Collection: Rapid
Throughput Standardized Evaluation of
Transmissible Risk for Substance Use
Disorder in Youth, Reference No
N44DA–12–5562, National Institute on
Drug Abuse (NIDA), National Institutes
of Health (NIH).
Need and Use of Information
Collection: This study will finalize the
development of the Transmissible
Liability Index (TLI), thereby advancing
the TLI from a research tool to a
practical instrument. The TLI is a
psychometric tool for detecting youth at
elevated risk for substance use disorder
(SUD). The TLI, a web-based platform
for assessing risk of SUD, is a highly
efficient tool both in terms of the
limited time commitment required as
well as its low cost. The inexpensive
and high efficiency of the TLI for
identifying youths in need of
prevention, and the strong cost-benefits
to society for SUD prevention, portend
strong demand for use in a variety of
populations including family and social
services, schools, mental health
facilities, and youth protection agencies.
To transform the TLI prototype into a
practical instrument, three core tasks
remain: (1) Standardization on a sample
(N=∼5,000) that is representative of the
general population to generate norms
that are specific to age, gender and
ethnicity; (2) Construct validity analysis
using standard parametric modeling
techniques to show that heritability
accounts for the major portion of
variance on TLI scores; the sample (150
identical and 150 fraternal twins) will
be representative of the same general
population characteristics identified
above; and (3) Psychometric analysis of
validity and reliability based on the
above data. Validating the TLI furthers
NIDA’s mission by legitimating the tool
for exploring the attitudes and social
predictors of addictive behaviors with
the intention of reducing or eliminating
drug-taking behavior. This research is
squarely within NIDA’s mission of
research on drug abuse and addiction,
as well as its focus on ensuring the
rapid and effective dissemination and
use of the results to significantly
improve efforts to stem substance use
disorder. To move the TLI from the
research domain to practical use
through commercial dissemination, the
research and development team (‘‘the
R&D team’’) needs to satisfy professional
quality standards consistent with
American Psychological Association
regulations. To satisfy those standards,
the R&D team must demonstrate the
reliability and internal validity of the
TLI against existing standardized
psychometric studies for youth
populations, ages 14 to 18. The 14-to-18
year old age range was selected because
it encompasses the years typically spent
in high school, which are known to be
the timeframe when substance use is
likely to begin and accelerates, often
leading to substance abuse disorder.
Notably, the peak period for the
manifestation of cannabis-use disorder
is age 18–19, and the past-yearprevalence for alcohol-use disorder is
age 20–22. The TLI is designed to
identify the propensity for these and
other substance abuse prior to
manifestation; as such, collecting data
from the high school age group (14–18
years old) is critical to identifying atrisk youths for the purposes of early
intervention. Thus, the TLI must be
tested with data collected from youth
populations, ages 14 to 18, comparable
to those in existing studies. Moreover,
the R&D team must provide
psychometric external validation for the
TLI through data collection from sets of
identical and fraternal twins.
Psychometric analyses are required to
show that the TLI performs according to
expectations. Accordingly, studies will
be performed on the collected
information to demonstrate (i) construct,
(ii) discriminative, (iii) concurrent, and
(iv) predictive validity.
OMB approval is requested for 2
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
3,083.
sroberts on DSK5SPTVN1PROD with NOTICES
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondent: Individuals and households
Number of
respondents
Parent of 14–17 year-old students: Consent Form .........................................
14–18 year-old students: School Survey (TLI) ................................................
14–18 year-old youths or their parents: Consent Form ..................................
14–18 year-old youths: Twins Survey (Demo/D&A) ........................................
5,000
........................
600
........................
VerDate Mar<15>2010
17:43 Mar 25, 2014
Jkt 232001
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
Average
burden per
response
(in hours)
Responses
per
respondent
E:\FR\FM\26MRN1.SGM
1
1
1
1
26MRN1
1/60
30/60
1/60
10/60
Annual hour
burden
83
2,500
10
100
16803
Federal Register / Vol. 79, No. 58 / Wednesday, March 26, 2014 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Type of respondent: Individuals and households
Number of
respondents
14–18 year-old youths: Twins Survey (Dysregulation) ....................................
14–18 year-old youths: Twins Survey (TLI) ....................................................
Average
burden per
response
(in hours)
Responses
per
respondent
........................
........................
1
1
Annual hour
burden
10/60
29/60
100
290
Dated: March 19, 2014.
Glenda J. Conroy,
Executive Officer (OM Director), NIDA, NIH.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2014–06728 Filed 3–25–14; 8:45 am]
National Institutes of Health
National Institutes of Health
BILLING CODE 4140–01–P
National Institute of Mental Health;
Notice of Closed Meeting
National Library of Medicine; Notice of
Meetings
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Alcohol Abuse
and Alcoholism; Notice of Closed
Meeting
sroberts on DSK5SPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Special
Emphasis Panel NIAAA Contract Review—
Solicitation PHS2014–1, Topic 088.
Date: April 22, 2014.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute on Alcohol Abuse
and Alcoholism, 5635 Fishers Lane,
(Teleconference), Rockville, MD 20852.
Contact Person: Ranga Srinivas, Ph.D.,
Chief, Extramural Project Review Branch,
EPRB, NIAAA, National Institutes of Health
5365 Fishers Lane, Room 2085, Rockville,
MD 20852, (301) 451–2067, srinivar@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.273, Alcohol Research
Programs; National Institutes of Health, HHS)
Dated: March 21, 2014.
Carolyn A. Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel; K22
Special Review.
Date: April 7, 2014.
Time: 12:00 p.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health
Neuroscience Center 6001 Executive
Boulevard Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: David M. Armstrong,
Ph.D., Scientific Review Officer Division of
Extramural Activities, National Institute of
Mental Health, NIH Neuroscience Center/
Room 6138/MSC 9608, 6001 Executive
Boulevard, Bethesda, MD 20892–9608, 301–
443–3534, armstrda@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
Dated: March 20, 2014.
Carolyn A. Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–06645 Filed 3–25–14; 8:45 am]
BILLING CODE 4140–01–P
[FR Doc. 2014–06644 Filed 3–25–14; 8:45 am]
BILLING CODE 4140–01–P
VerDate Mar<15>2010
17:43 Mar 25, 2014
Jkt 232001
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of meetings of the Board of
Regents of the National Library of
Medicine.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 USC,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Regents of
the National Library of Medicine Extramural
Programs Subcommittee.
Date: May 12, 2014.
Closed: 2:30 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Library of Medicine,
Building 38, 2nd Floor, Conference Room B,
8600 Rockville Pike, Bethesda, MD 20892.
Contact Person: Donald A.B. Lindberg, MD,
Director, National Library of Medicine, 8600
Rockville Pike, Bethesda, MD 20892, 301–
496–6221, lindberg@mail.nih.gov.
Name of Committee: Board of Regents of
the National Library of Medicine
Subcommittee on Outreach and Public
Information.
Date: May 13, 2014.
Open: 7:45 a.m. to 8:45 a.m.
Agenda: To review and discuss outreach
activities.
Place: National Library of Medicine,
Building 38, 2nd Floor, Conference Room B,
8600 Rockville Pike, Bethesda, MD 20892.
E:\FR\FM\26MRN1.SGM
26MRN1
Agencies
[Federal Register Volume 79, Number 58 (Wednesday, March 26, 2014)]
[Notices]
[Pages 16802-16803]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-06728]
[[Page 16802]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day Comment Request Rapid
Throughput Standardized Evaluation of Transmissible Risk for Substance
Use Disorder in Youth
SUMMARY: Under the provisions of Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National Institutes of Health (NIH) has
submitted to the Office of Management and Budget (OMB) a request for
review and approval of the information collection listed below. This
proposed information collection was previously published in the Federal
Register on December 3, 2013, page 72682-72683 and allowed 60-days for
public comment. One public comment was received. The purpose of this
notice is to allow an additional 30 days for public comment. The
National Institute Drug Abuse (NIDA), National Institutes of Health,
may not conduct or sponsor, and the respondent is not required to
respond to, an information collection that has been extended, revised,
or implemented on or after October 1, 1995, unless it displays a
currently valid OMB control number.
Direct Comments to OMB: Written comments and/or suggestions
regarding the item(s) contained in this notice, especially regarding
the estimated public burden and associated response time, should be
directed to the: Office of Management and Budget, Office of Regulatory
Affairs, OIRA_submission@omb.eop.gov or by fax to 202-395-6974,
Attention: NIH Desk Officer.
DATES: Comment Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 30-days
of the date of this publication.
FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data
collection plans and instructions, contact Dr. Augie Diana, Health
Scientist Administrator, Prevention Research Branch, Division of
Epidemiology, Services, and Prevention Research, NIDA, NIH, 6001
Executive Boulevard, Room 5163, Bethesda, MD 20892, or call non-toll-
free number (301) 443-1942 or Email your request, including your
address to: dianaa@nida.nih.gov. Formal request for additional plans
and instruments must be requested in writing.
Proposed Collection: Rapid Throughput Standardized Evaluation of
Transmissible Risk for Substance Use Disorder in Youth, Reference No
N44DA-12-5562, National Institute on Drug Abuse (NIDA), National
Institutes of Health (NIH).
Need and Use of Information Collection: This study will finalize
the development of the Transmissible Liability Index (TLI), thereby
advancing the TLI from a research tool to a practical instrument. The
TLI is a psychometric tool for detecting youth at elevated risk for
substance use disorder (SUD). The TLI, a web-based platform for
assessing risk of SUD, is a highly efficient tool both in terms of the
limited time commitment required as well as its low cost. The
inexpensive and high efficiency of the TLI for identifying youths in
need of prevention, and the strong cost-benefits to society for SUD
prevention, portend strong demand for use in a variety of populations
including family and social services, schools, mental health
facilities, and youth protection agencies. To transform the TLI
prototype into a practical instrument, three core tasks remain: (1)
Standardization on a sample (N=~5,000) that is representative of the
general population to generate norms that are specific to age, gender
and ethnicity; (2) Construct validity analysis using standard
parametric modeling techniques to show that heritability accounts for
the major portion of variance on TLI scores; the sample (150 identical
and 150 fraternal twins) will be representative of the same general
population characteristics identified above; and (3) Psychometric
analysis of validity and reliability based on the above data.
Validating the TLI furthers NIDA's mission by legitimating the tool for
exploring the attitudes and social predictors of addictive behaviors
with the intention of reducing or eliminating drug-taking behavior.
This research is squarely within NIDA's mission of research on drug
abuse and addiction, as well as its focus on ensuring the rapid and
effective dissemination and use of the results to significantly improve
efforts to stem substance use disorder. To move the TLI from the
research domain to practical use through commercial dissemination, the
research and development team (``the R&D team'') needs to satisfy
professional quality standards consistent with American Psychological
Association regulations. To satisfy those standards, the R&D team must
demonstrate the reliability and internal validity of the TLI against
existing standardized psychometric studies for youth populations, ages
14 to 18. The 14-to-18 year old age range was selected because it
encompasses the years typically spent in high school, which are known
to be the timeframe when substance use is likely to begin and
accelerates, often leading to substance abuse disorder. Notably, the
peak period for the manifestation of cannabis-use disorder is age 18-
19, and the past-year-prevalence for alcohol-use disorder is age 20-22.
The TLI is designed to identify the propensity for these and other
substance abuse prior to manifestation; as such, collecting data from
the high school age group (14-18 years old) is critical to identifying
at-risk youths for the purposes of early intervention. Thus, the TLI
must be tested with data collected from youth populations, ages 14 to
18, comparable to those in existing studies. Moreover, the R&D team
must provide psychometric external validation for the TLI through data
collection from sets of identical and fraternal twins. Psychometric
analyses are required to show that the TLI performs according to
expectations. Accordingly, studies will be performed on the collected
information to demonstrate (i) construct, (ii) discriminative, (iii)
concurrent, and (iv) predictive validity.
OMB approval is requested for 2 years. There are no costs to
respondents other than their time. The total estimated annualized
burden hours are 3,083.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Responses per burden per Annual hour
Type of respondent: Individuals and households respondents respondent response (in burden
hours)
----------------------------------------------------------------------------------------------------------------
Parent of 14-17 year-old students: Consent Form. 5,000 1 1/60 83
14-18 year-old students: School Survey (TLI).... .............. 1 30/60 2,500
14-18 year-old youths or their parents: Consent 600 1 1/60 10
Form...........................................
14-18 year-old youths: Twins Survey (Demo/D&A).. .............. 1 10/60 100
[[Page 16803]]
14-18 year-old youths: Twins Survey .............. 1 10/60 100
(Dysregulation)................................
14-18 year-old youths: Twins Survey (TLI)....... .............. 1 29/60 290
----------------------------------------------------------------------------------------------------------------
Dated: March 19, 2014.
Glenda J. Conroy,
Executive Officer (OM Director), NIDA, NIH.
[FR Doc. 2014-06728 Filed 3-25-14; 8:45 am]
BILLING CODE 4140-01-P